Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 117 entries
Sorted by: Best Match Show Resources per page
Down-Regulation of Serum High-Mobility Group Box 1 Protein in Patients with Pulmonary Tuberculosis and Nontuberculous Mycobacterial Lung Disease.

Tuberculosis and respiratory diseases

Kim SY, Koh WJ, Park HY, Jeon K, Lee SY, Yim JJ, Shin SJ.
PMID: 28416955
Tuberc Respir Dis (Seoul). 2017 Apr;80(2):153-158. doi: 10.4046/trd.2017.80.2.153. Epub 2017 Mar 31.

BACKGROUND: Recently, increased levels of high-mobility group box 1 protein (HMGB1) have been identified in various inflammatory conditions and infections. However, no studies have evaluated the HMGB1 level in nontuberculous mycobacterial (NTM) lung disease, and compared it to mycobacterial...

Cite
Kim SY, Koh WJ, Park HY, et al. Down-Regulation of Serum High-Mobility Group Box 1 Protein in Patients with Pulmonary Tuberculosis and Nontuberculous Mycobacterial Lung Disease. Tuberc Respir Dis (Seoul). 2017;80(2):153-158doi: 10.4046/trd.2017.80.2.153.
Kim, S. Y., Koh, W. J., Park, H. Y., Jeon, K., Lee, S. Y., Yim, J. J., & Shin, S. J. (2017). Down-Regulation of Serum High-Mobility Group Box 1 Protein in Patients with Pulmonary Tuberculosis and Nontuberculous Mycobacterial Lung Disease. Tuberculosis and respiratory diseases, 80(2), 153-158. https://doi.org/10.4046/trd.2017.80.2.153
Kim, Su-Young, et al. "Down-Regulation of Serum High-Mobility Group Box 1 Protein in Patients with Pulmonary Tuberculosis and Nontuberculous Mycobacterial Lung Disease." Tuberculosis and respiratory diseases vol. 80,2 (2017): 153-158. doi: https://doi.org/10.4046/trd.2017.80.2.153
Kim SY, Koh WJ, Park HY, Jeon K, Lee SY, Yim JJ, Shin SJ. Down-Regulation of Serum High-Mobility Group Box 1 Protein in Patients with Pulmonary Tuberculosis and Nontuberculous Mycobacterial Lung Disease. Tuberc Respir Dis (Seoul). 2017 Apr;80(2):153-158. doi: 10.4046/trd.2017.80.2.153. Epub 2017 Mar 31. PMID: 28416955; PMCID: PMC5392486.
Copy Download .nbib Format: NLM
HMGB1 is negatively correlated with the development of endometrial carcinoma and prevents cancer cell invasion and metastasis by inhibiting the process of epithelial-to-mesenchymal transition.

OncoTargets and therapy

Luan X, Ma C, Wang P, Lou F.
PMID: 28424555
Onco Targets Ther. 2017 Mar 03;10:1389-1402. doi: 10.2147/OTT.S123085. eCollection 2017.

High-mobility group box protein 1 (HMGB1), a nuclear protein that plays a significant role in DNA architecture and transcription, was correlated with the progression of some types of cancer. However, the role of HMGB1 in endometrial cancer cell invasion...

Cite
Luan X, Ma C, Wang P, et al. HMGB1 is negatively correlated with the development of endometrial carcinoma and prevents cancer cell invasion and metastasis by inhibiting the process of epithelial-to-mesenchymal transition. Onco Targets Ther. 2017;10:1389-1402doi: 10.2147/OTT.S123085.
Luan, X., Ma, C., Wang, P., & Lou, F. (2017). HMGB1 is negatively correlated with the development of endometrial carcinoma and prevents cancer cell invasion and metastasis by inhibiting the process of epithelial-to-mesenchymal transition. OncoTargets and therapy, 101389-1402. https://doi.org/10.2147/OTT.S123085
Luan, Xiaorong, et al. "HMGB1 is negatively correlated with the development of endometrial carcinoma and prevents cancer cell invasion and metastasis by inhibiting the process of epithelial-to-mesenchymal transition." OncoTargets and therapy vol. 10 (2017): 1389-1402. doi: https://doi.org/10.2147/OTT.S123085
Luan X, Ma C, Wang P, Lou F. HMGB1 is negatively correlated with the development of endometrial carcinoma and prevents cancer cell invasion and metastasis by inhibiting the process of epithelial-to-mesenchymal transition. Onco Targets Ther. 2017 Mar 03;10:1389-1402. doi: 10.2147/OTT.S123085. eCollection 2017. PMID: 28424555; PMCID: PMC5344438.
Copy Download .nbib Format: NLM
Role of high-mobility group box 1 in patients with acute obstructive suppurative cholangitis-induced sepsis.

Journal of inflammation research

Singh A, Feng Y, Mahato N, Li J, Wu C, Gong J.
PMID: 25792849
J Inflamm Res. 2015 Mar 11;8:71-7. doi: 10.2147/JIR.S77539. eCollection 2015.

BACKGROUND: High-mobility group box 1 (HMGB1) is a proinflammatory cytokine that plays an active role during the pathogenesis of inflammatory processes. The primary aim of this study was to detect whether HMGB1 is involved in the pathogenesis of acute...

Cite
Singh A, Feng Y, Mahato N, et al. Role of high-mobility group box 1 in patients with acute obstructive suppurative cholangitis-induced sepsis. J Inflamm Res. 2015;8:71-7doi: 10.2147/JIR.S77539.
Singh, A., Feng, Y., Mahato, N., Li, J., Wu, C., & Gong, J. (2015). Role of high-mobility group box 1 in patients with acute obstructive suppurative cholangitis-induced sepsis. Journal of inflammation research, 871-7. https://doi.org/10.2147/JIR.S77539
Singh, Akanand, et al. "Role of high-mobility group box 1 in patients with acute obstructive suppurative cholangitis-induced sepsis." Journal of inflammation research vol. 8 (2015): 71-7. doi: https://doi.org/10.2147/JIR.S77539
Singh A, Feng Y, Mahato N, Li J, Wu C, Gong J. Role of high-mobility group box 1 in patients with acute obstructive suppurative cholangitis-induced sepsis. J Inflamm Res. 2015 Mar 11;8:71-7. doi: 10.2147/JIR.S77539. eCollection 2015. PMID: 25792849; PMCID: PMC4362899.
Copy Download .nbib Format: NLM
Expression of high mobility group box 1 protein predicts a poorer prognosis for patients with osteosarcoma.

Oncology letters

He J, Zhang P, Li Q, Zhou D, Liu P.
PMID: 26870206
Oncol Lett. 2016 Jan;11(1):293-298. doi: 10.3892/ol.2015.3907. Epub 2015 Nov 10.

The high mobility group box 1 (HMGB1) protein functions as an extracellular signaling molecule that is critical in inflammation and carcinogenesis. The HMGB1 protein is actively secreted by natural killer cells, monocytes and macrophages, and acts as an inflammatory...

Cite
He J, Zhang P, Li Q, et al. Expression of high mobility group box 1 protein predicts a poorer prognosis for patients with osteosarcoma. Oncol Lett. 2015;11(1):293-298doi: 10.3892/ol.2015.3907.
He, J., Zhang, P., Li, Q., Zhou, D., & Liu, P. (2016). Expression of high mobility group box 1 protein predicts a poorer prognosis for patients with osteosarcoma. Oncology letters, 11(1), 293-298. https://doi.org/10.3892/ol.2015.3907
He, Jiliang, et al. "Expression of high mobility group box 1 protein predicts a poorer prognosis for patients with osteosarcoma." Oncology letters vol. 11,1 (2016): 293-298. doi: https://doi.org/10.3892/ol.2015.3907
He J, Zhang P, Li Q, Zhou D, Liu P. Expression of high mobility group box 1 protein predicts a poorer prognosis for patients with osteosarcoma. Oncol Lett. 2016 Jan;11(1):293-298. doi: 10.3892/ol.2015.3907. Epub 2015 Nov 10. PMID: 26870206; PMCID: PMC4727050.
Copy Download .nbib Format: NLM
High mobility group box 1: a novel mediator of Th2-type response-induced airway inflammation of acute allergic asthma.

Journal of thoracic disease

Ma L, Zeng J, Mo B, Wang C, Huang J, Sun Y, Yu Y, Liu S.
PMID: 26623095
J Thorac Dis. 2015 Oct;7(10):1732-41. doi: 10.3978/j.issn.2072-1439.2015.10.18.

BACKGROUND: High mobility group box 1 (HMGB1) is an inflammatory mediator involved into the advanced stage of systemic inflammatory response syndrome (SIRS), and is over-expressed in bacterial sepsis and hemorrhagic shock. Recently, it has been found that the HMGB1...

Cite
Ma L, Zeng J, Mo B, et al. High mobility group box 1: a novel mediator of Th2-type response-induced airway inflammation of acute allergic asthma. J Thorac Dis. 2015;7(10):1732-41doi: 10.3978/j.issn.2072-1439.2015.10.18.
Ma, L., Zeng, J., Mo, B., Wang, C., Huang, J., Sun, Y., Yu, Y., & Liu, S. (2015). High mobility group box 1: a novel mediator of Th2-type response-induced airway inflammation of acute allergic asthma. Journal of thoracic disease, 7(10), 1732-41. https://doi.org/10.3978/j.issn.2072-1439.2015.10.18
Ma, Libing, et al. "High mobility group box 1: a novel mediator of Th2-type response-induced airway inflammation of acute allergic asthma." Journal of thoracic disease vol. 7,10 (2015): 1732-41. doi: https://doi.org/10.3978/j.issn.2072-1439.2015.10.18
Ma L, Zeng J, Mo B, Wang C, Huang J, Sun Y, Yu Y, Liu S. High mobility group box 1: a novel mediator of Th2-type response-induced airway inflammation of acute allergic asthma. J Thorac Dis. 2015 Oct;7(10):1732-41. doi: 10.3978/j.issn.2072-1439.2015.10.18. PMID: 26623095; PMCID: PMC4635276.
Copy Download .nbib Format: NLM
Natural Killer (NK)/melanoma cell interaction induces NK-mediated release of chemotactic High Mobility Group Box-1 (HMGB1) capable of amplifying NK cell recruitment.

Oncoimmunology

Parodi M, Pedrazzi M, Cantoni C, Averna M, Patrone M, Cavaletto M, Spertino S, Pende D, Balsamo M, Pietra G, Sivori S, Carlomagno S, Mingari MC, Moretta L, Sparatore B, Vitale M.
PMID: 26587323
Oncoimmunology. 2015 May 29;4(12):e1052353. doi: 10.1080/2162402X.2015.1052353. eCollection 2015 Dec.

In this study we characterize a new mechanism by which Natural Killer (NK) cells may amplify their recruitment to tumors. We show that NK cells, upon interaction with melanoma cells, can release a chemotactic form of High Mobility Group...

Cite
Parodi M, Pedrazzi M, Cantoni C, et al. Natural Killer (NK)/melanoma cell interaction induces NK-mediated release of chemotactic High Mobility Group Box-1 (HMGB1) capable of amplifying NK cell recruitment. Oncoimmunology. 2015;4(12):e1052353doi: 10.1080/2162402X.2015.1052353.
Parodi, M., Pedrazzi, M., Cantoni, C., Averna, M., Patrone, M., Cavaletto, M., Spertino, S., Pende, D., Balsamo, M., Pietra, G., Sivori, S., Carlomagno, S., Mingari, M. C., Moretta, L., Sparatore, B., & Vitale, M. (2015). Natural Killer (NK)/melanoma cell interaction induces NK-mediated release of chemotactic High Mobility Group Box-1 (HMGB1) capable of amplifying NK cell recruitment. Oncoimmunology, 4(12), e1052353. https://doi.org/10.1080/2162402X.2015.1052353
Parodi, Monica, et al. "Natural Killer (NK)/melanoma cell interaction induces NK-mediated release of chemotactic High Mobility Group Box-1 (HMGB1) capable of amplifying NK cell recruitment." Oncoimmunology vol. 4,12 (2015): e1052353. doi: https://doi.org/10.1080/2162402X.2015.1052353
Parodi M, Pedrazzi M, Cantoni C, Averna M, Patrone M, Cavaletto M, Spertino S, Pende D, Balsamo M, Pietra G, Sivori S, Carlomagno S, Mingari MC, Moretta L, Sparatore B, Vitale M. Natural Killer (NK)/melanoma cell interaction induces NK-mediated release of chemotactic High Mobility Group Box-1 (HMGB1) capable of amplifying NK cell recruitment. Oncoimmunology. 2015 May 29;4(12):e1052353. doi: 10.1080/2162402X.2015.1052353. eCollection 2015 Dec. PMID: 26587323; PMCID: PMC4635845.
Copy Download .nbib Format: NLM
Disruption of a Regulatory Network Consisting of Neutrophils and Platelets Fosters Persisting Inflammation in Rheumatic Diseases.

Frontiers in immunology

Maugeri N, Rovere-Querini P, Manfredi AA.
PMID: 27242789
Front Immunol. 2016 May 19;7:182. doi: 10.3389/fimmu.2016.00182. eCollection 2016.

A network of cellular interactions that involve blood leukocytes and platelets maintains vessel homeostasis. It plays a critical role in the response to invading microbes by recruiting intravascular immunity and through the generation of neutrophil extracellular traps (NETs) and...

Cite
Maugeri N, Rovere-Querini P, Manfredi AA. Disruption of a Regulatory Network Consisting of Neutrophils and Platelets Fosters Persisting Inflammation in Rheumatic Diseases. Front Immunol. 2016;7:182doi: 10.3389/fimmu.2016.00182.
Maugeri, N., Rovere-Querini, P., & Manfredi, A. A. (2016). Disruption of a Regulatory Network Consisting of Neutrophils and Platelets Fosters Persisting Inflammation in Rheumatic Diseases. Frontiers in immunology, 7182. https://doi.org/10.3389/fimmu.2016.00182
Maugeri, Norma, et al. "Disruption of a Regulatory Network Consisting of Neutrophils and Platelets Fosters Persisting Inflammation in Rheumatic Diseases." Frontiers in immunology vol. 7 (2016): 182. doi: https://doi.org/10.3389/fimmu.2016.00182
Maugeri N, Rovere-Querini P, Manfredi AA. Disruption of a Regulatory Network Consisting of Neutrophils and Platelets Fosters Persisting Inflammation in Rheumatic Diseases. Front Immunol. 2016 May 19;7:182. doi: 10.3389/fimmu.2016.00182. eCollection 2016. PMID: 27242789; PMCID: PMC4871869.
Copy Download .nbib Format: NLM
Association between follicular fluid levels of HMGB1 protein and outcomes in patients undergoing .

Experimental and therapeutic medicine

Li S, Yin T, Li W, Yang J, Xu W, Zhou D.
PMID: 26136867
Exp Ther Med. 2015 May;9(5):1611-1616. doi: 10.3892/etm.2015.2369. Epub 2015 Mar 18.

The aim of the present study was to evaluate the association between follicular fluid (FF) levels of high-mobility group box 1 (HMGB1) protein and the reproductive outcome in patients undergoing

Cite
Li S, Yin T, Li W, et al. Association between follicular fluid levels of HMGB1 protein and outcomes in patients undergoing . Exp Ther Med. 2015;9(5):1611-1616doi: 10.3892/etm.2015.2369.
Li, S., Yin, T., Li, W., Yang, J., Xu, W., & Zhou, D. (2015). Association between follicular fluid levels of HMGB1 protein and outcomes in patients undergoing . Experimental and therapeutic medicine, 9(5), 1611-1616. https://doi.org/10.3892/etm.2015.2369
Li, Saijiao, et al. "Association between follicular fluid levels of HMGB1 protein and outcomes in patients undergoing ." Experimental and therapeutic medicine vol. 9,5 (2015): 1611-1616. doi: https://doi.org/10.3892/etm.2015.2369
Li S, Yin T, Li W, Yang J, Xu W, Zhou D. Association between follicular fluid levels of HMGB1 protein and outcomes in patients undergoing . Exp Ther Med. 2015 May;9(5):1611-1616. doi: 10.3892/etm.2015.2369. Epub 2015 Mar 18. PMID: 26136867; PMCID: PMC4471704.
Copy Download .nbib Format: NLM
Markedly Increased High-Mobility Group Box 1 Protein in a Patient with Small-for-Size Syndrome.

Case reports in transplantation

Craig DG, Lee P, Pryde EA, Hidalgo E, Hayes PC, Wigmore SJ, Forbes SJ, Simpson KJ.
PMID: 24600525
Case Rep Transplant. 2014;2014:272498. doi: 10.1155/2014/272498. Epub 2014 Jan 29.

Background. Small-for-size syndrome (SFSS) occurs in the presence of insufficient liver mass to maintain normal function after liver transplantation. Murine mortality following 85% hepatectomy can be reduced by the use of soluble receptor for advanced glycation end products (sRAGE)...

Cite
Craig DG, Lee P, Pryde EA, et al. Markedly Increased High-Mobility Group Box 1 Protein in a Patient with Small-for-Size Syndrome. Case Rep Transplant. 2014;2014:272498doi: 10.1155/2014/272498.
Craig, D. G., Lee, P., Pryde, E. A., Hidalgo, E., Hayes, P. C., Wigmore, S. J., Forbes, S. J., & Simpson, K. J. (2014). Markedly Increased High-Mobility Group Box 1 Protein in a Patient with Small-for-Size Syndrome. Case reports in transplantation, 2014272498. https://doi.org/10.1155/2014/272498
Craig, Darren G, et al. "Markedly Increased High-Mobility Group Box 1 Protein in a Patient with Small-for-Size Syndrome." Case reports in transplantation vol. 2014 (2014): 272498. doi: https://doi.org/10.1155/2014/272498
Craig DG, Lee P, Pryde EA, Hidalgo E, Hayes PC, Wigmore SJ, Forbes SJ, Simpson KJ. Markedly Increased High-Mobility Group Box 1 Protein in a Patient with Small-for-Size Syndrome. Case Rep Transplant. 2014;2014:272498. doi: 10.1155/2014/272498. Epub 2014 Jan 29. PMID: 24600525; PMCID: PMC3926239.
Copy Download .nbib Format: NLM
High Mobility Group box-1 (HMGB1) Protein As a Biomarker for Acute Cholecystitis.

Reports of biochemistry & molecular biology

Amini M, Pakdaman A, Shapoori S, Mosayebi G.
PMID: 30805401
Rep Biochem Mol Biol. 2019 Jan;7(2):204-209.

BACKGROUND: Acute cholecystitis is defined as gallbladder inflammation caused by obstruction of the cystic duct. The pro-inflammatory cytokine, high mobility group box-1 (HMGB1), has been found to hold critical roles in the pathogenesis of several different inflammatory diseases. This...

Cite
Amini M, Pakdaman A, Shapoori S, et al. High Mobility Group box-1 (HMGB1) Protein As a Biomarker for Acute Cholecystitis. Rep Biochem Mol Biol. 2019;7(2):204-209
Amini, M., Pakdaman, A., Shapoori, S., & Mosayebi, G. (2019). High Mobility Group box-1 (HMGB1) Protein As a Biomarker for Acute Cholecystitis. Reports of biochemistry & molecular biology, 7(2), 204-209.
Amini, Mahmoud, et al. "High Mobility Group box-1 (HMGB1) Protein As a Biomarker for Acute Cholecystitis." Reports of biochemistry & molecular biology vol. 7,2 (2019): 204-209.
Amini M, Pakdaman A, Shapoori S, Mosayebi G. High Mobility Group box-1 (HMGB1) Protein As a Biomarker for Acute Cholecystitis. Rep Biochem Mol Biol. 2019 Jan;7(2):204-209. PMID: 30805401; PMCID: PMC6374064.
Copy Download .nbib Format: NLM
Molecular modelling and docking of Mus musculus HMGB1 inflammatory protein with CGA.

Bioinformation

Tripathi A, Shrinet K, Singh VK, Kumar A.
PMID: 31485132
Bioinformation. 2019 Jul 31;15(7):467-473. doi: 10.6026/97320630015467. eCollection 2019.

Recently, High Mobility Group Box1 (HMGB1) protein has been reported as an inflammatory cytokine present in all nucleated cells with crucial role in the genesis and promotion of cancer. No HMGB1 protein mice model and its active site details...

Cite
Tripathi A, Shrinet K, Singh VK, et al. Molecular modelling and docking of Mus musculus HMGB1 inflammatory protein with CGA. Bioinformation. 2019;15(7):467-473doi: 10.6026/97320630015467.
Tripathi, A., Shrinet, K., Singh, V. K., & Kumar, A. (2019). Molecular modelling and docking of Mus musculus HMGB1 inflammatory protein with CGA. Bioinformation, 15(7), 467-473. https://doi.org/10.6026/97320630015467
Tripathi, Alok, et al. "Molecular modelling and docking of Mus musculus HMGB1 inflammatory protein with CGA." Bioinformation vol. 15,7 (2019): 467-473. doi: https://doi.org/10.6026/97320630015467
Tripathi A, Shrinet K, Singh VK, Kumar A. Molecular modelling and docking of Mus musculus HMGB1 inflammatory protein with CGA. Bioinformation. 2019 Jul 31;15(7):467-473. doi: 10.6026/97320630015467. eCollection 2019. PMID: 31485132; PMCID: PMC6704330.
Copy Download .nbib Format: NLM
Biomarkers in the prevention and follow-up of workers exposed to asbestos.

Journal of thoracic disease

Foddis R, Bonotti A, Landi S, Fallahi P, Guglielmi G, Cristaudo A.
PMID: 29507806
J Thorac Dis. 2018 Jan;10:S360-S368. doi: 10.21037/jtd.2017.12.17.

Although in most developed countries the use of asbestos is banned, there is still a consistent portion of the world where asbestos extraction, trading and manufacturing of asbestos-made products is largely diffuse. Worldwide, hundreds of millions of people are...

Cite
Foddis R, Bonotti A, Landi S, et al. Biomarkers in the prevention and follow-up of workers exposed to asbestos. J Thorac Dis. 2018;10:S360-S368doi: 10.21037/jtd.2017.12.17.
Foddis, R., Bonotti, A., Landi, S., Fallahi, P., Guglielmi, G., & Cristaudo, A. (2018). Biomarkers in the prevention and follow-up of workers exposed to asbestos. Journal of thoracic disease, 10S360-S368. https://doi.org/10.21037/jtd.2017.12.17
Foddis, Rudy, et al. "Biomarkers in the prevention and follow-up of workers exposed to asbestos." Journal of thoracic disease vol. 10 (2018): S360-S368. doi: https://doi.org/10.21037/jtd.2017.12.17
Foddis R, Bonotti A, Landi S, Fallahi P, Guglielmi G, Cristaudo A. Biomarkers in the prevention and follow-up of workers exposed to asbestos. J Thorac Dis. 2018 Jan;10:S360-S368. doi: 10.21037/jtd.2017.12.17. PMID: 29507806; PMCID: PMC5830548.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 117 entries